Literature DB >> 32633367

The expression and clinical significance of B7-H3 and miR-145 in lung cancer patients with malignant pleural effusion.

L Huang1.   

Abstract

OBJECTIVE: To investigate the expression and clinical significance of costimulatory molecule B7-H3 and microRNA-145 (miR-145) in lung cancer patients with malignant pleural effusion. PATIENTS AND METHODS: A total of 100 cases of patients with lung cancer who admitted to our hospital for treatment from March 2017 to September 2018 were selected. Forty-nine cases of patients diagnosed with malignant pleural effusion were included in the study group, and 51 cases with benign pleural effusion in the control group. The content of B7-H3 in pleural effusion of the two groups was detected by enzyme-linked immunosorbent assay (ELISA), and the expression of miR-145 in pleural effusion of the two groups was analyzed by Real-time quantitative PCR (qRT-PCR). The relationships between the expressions of B7-H3 and miR-145 and the clinicopathological characteristics were analyzed. The diagnostic value of B7-H3 and miR-145 in lung cancer was analyzed.
RESULTS: The expression level of B7-H3 in the study group was significantly higher than that in the control group (p<0.050), while the expression level of miR-145 was significantly lower than that in the control group (p<0.050). The expression levels of B7-H3 and miR-145 in the study group were correlated with lymph node metastasis, differentiation degree of lung cancer and TNM stage (p<0.001). The sensitivity and specificity of miR-145 in single diagnosis of lung cancer were 64.71% and 79.59%, respectively. The sensitivity and specificity of B7-H3 in single diagnosis of lung cancer were 80.39% and 61.22%, respectively.
CONCLUSIONS: B7-H3 and miR-145 are abnormally expressed in lung cancer, and are closely related to the lymphatic metastasis, differentiation degree and TNM stage of lung cancer. They may be potential markers for the diagnosis of malignant pleural effusion in lung cancer in the future.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32633367     DOI: 10.26355/eurrev_202006_21664

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

1.  A Novel Prognostic and Predictive Signature for Lung Adenocarcinoma Derived from Combined Hypoxia and Infiltrating Immune Cell-Related Genes in TCGA Patients.

Authors:  Xiaofeng Wu; Jing Zhu; Wei Liu; Meng Jin; Mengqing Xiong; Ke Hu
Journal:  Int J Gen Med       Date:  2021-12-30

2.  Diagnostic value of periostin in lung cancer-related malignant pleural effusion.

Authors:  Jinjin Zhang; Tongtong Zha; Na Zhang; Gengyun Sun
Journal:  J Clin Lab Anal       Date:  2021-12-27       Impact factor: 2.352

3.  Circ_0001998 Regulates the Proliferation, Invasion, and Apoptosis of Lung Adenocarcinoma via Sponging miR-145.

Authors:  Qiang Shi; Jian-Gang Ju
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-11       Impact factor: 2.650

Review 4.  The Features of Immune Checkpoint Gene Regulation by microRNA in Cancer.

Authors:  Fatimat Kipkeeva; Tatyana Muzaffarova; Alexandra Korotaeva; Danzan Mansorunov; Pavel Apanovich; Maxim Nikulin; Olga Malikhova; Ivan Stilidi; Alexander Karpukhin
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.